Holen Sie sich die Stockscreener-App
1.0799
2.85%
0.0299
Schlusskurs vom Vortag:
$1.05
Offen:
$1.09
24-Stunden-Volumen:
7,900
Relative Volume:
0.66
Marktkapitalisierung:
$9.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-1.5227
EPS:
-0.7092
Netto-Cashflow:
-
1W Leistung:
-7.70%
1M Leistung:
-11.48%
6M Leistung:
-44.94%
1J Leistung:
-54.63%
1-Tages-Spanne:
$1.07
$1.10
1-Wochen-Bereich:
$1.05
$1.24
52-Wochen-Spanne:
$1.01
$5.41
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Firmenname
Alterity Therapeutics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ATHE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ATHE | 1.08 | 9.18M | 0 | 0 | 0 | -0.7092 |
| VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alterity Therapeutics Ltd Adr Aktie (ATHE) Neueste Nachrichten
Alterity Therapeutics announces change in company secretary - Investing.com
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com
ATHE’s Stock Market Adventure: -14.26% YTD Growth Amidst Volatility - The InvestChronicle
Alterity reports positive Phase 2 trial interim data - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alphabet stock cited by TD Cowen amid potential Wiz acquisition - Investing.com
Alterity Therapeutics announces trading halt By Investing.com - Investing.com
Avenue Supermarts stock target raised by Nuvama, still a Hold - Investing.com India
Wolfe Research keeps Peerperform rating on Goldman Sachs stock, notes mixed Q2 earnings - Investing.com India
RBC Capital sees growth potential in Bowhead Specialty shares - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024 - Stockhead
Closing Bell: The ASX is slightly higher, but not much cooler on Monday - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
Check up: Enthusiasm rather than news is moving health stocks - Stockhead
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For An - Benzinga
54 Biggest Movers From YesterdayAcasti Pharma (NASDAQ:ACST), Alterity Therapeutics (NASDAQ:ATHE) - Benzinga
Finanzdaten der Alterity Therapeutics Ltd Adr-Aktie (ATHE)
Es liegen keine Finanzdaten für Alterity Therapeutics Ltd Adr (ATHE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):